In 2024, Bactiguard completed the strategic shift needed to enable the company to be the premier choice for both current and future partners. This transformation delivered positive financial results and positioned Bactiguard for growth. The company achieved EBITDA profitability, which was a core commitment to its shareholders, along with positive cash flow from operating activities. Reaching these milestones marks a significant achievement, allowing Bactiguard to further develop its business and infection prevention technology platform. Most importantly, it validated the strength of the company’s business model and license-focused strategy.
“Through our license-focused strategy, we strive to be the premier partner for leading MedTech companies by delivering our knowledge and capabilities to enhance partner medical devices. Continuously strengthening our core competencies remains essential to deepening partnerships and is a top priority for us also going forward. The synergies are clear – driving positive outcomes for our license partners also benefits Bactiguard, healthcare providers, and patients alike.” Christine Lind comments in her CEO statement.
Bactiguard Holding AB’s Annual and Sustainability Report 2024
